IL-2/CD80 Fusion Medium for Bead-Free T Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing T cell therapeutic agents like Kymriah face potential side effects due to the use of CD3/CD28 antibody-bound magnetic beads and the risk of replication-competent lentivirus transmission, necessitating a safer alternative for T cell proliferation and activation.
Innovation Solution
A culture medium utilizing a fusion protein dimer comprising an IL-2 protein or variant and a CD80 protein or fragment is used to proliferate T cells, eliminating the need for CD3/CD28 antibodies and reducing the risk of impurities and viral transmission.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If CD3/CD28 antibody-bound magnetic beads are used for T cell proliferation, then T cell activation and proliferation are enhanced, but acute toxicity and impurity contamination occur
Solution Approach 1:
The patent extracts and eliminates the harmful magnetic bead component from the T cell activation system while retaining the essential co-stimulatory function through soluble CD80-Fc fusion protein, thereby removing the source of acute toxicity and impurity contamination
Solution Approach 2:
The patent introduces CD80-Fc fusion protein as an intermediary molecule that mediates T cell activation through CD28 binding, replacing the direct magnetic bead-antibody-T cell interaction and eliminating the harmful effects of magnetic beads while maintaining proliferation efficacy
2Productivity
If replication-competent lentivirus is used for T cell transduction, then CAR-T cell production is achieved, but viral transmission and infectious risks arise
Solution Approach 1:
The patent converts the potential harm of replication-competent lentivirus into benefit by using replication-defective lentiviral vectors with self-inactivating (SIN) designs, where the very features that could cause harm (viral integration capability) are modified to eliminate infectious risk while maintaining transduction efficiency
Solution Approach 2:
The patent changes critical parameters of the lentiviral vector system including using SIN designs, pseudotyping with safe envelops, and controlling transduction conditions to achieve CAR-T cell production without generating replication-competent virus
3Productivity
If magnetic beads are used for T cell stimulation, then T cell activation is enhanced, but washing steps and purification processes are required
Solution Approach 1:
The patent extracts the magnetic bead component entirely from the system, replacing it with soluble CD80-Fc fusion protein that can be added to culture medium without requiring magnetic bead handling, washing, or purification steps
Solution Approach 2:
The patent replaces the mechanical magnetic bead system requiring physical manipulation and washing steps with a biochemical soluble protein system that can be delivered through simple medium addition, eliminating complex mechanical operations
Data Source
AI summary
The present invention relates to a composition for proliferating a T cells, containing a fusion protein dimer comprising IL-2 protein or a variant thereof and CD80 protein or a fragment thereof, and to a method for culturing T cells using same. The T cells cultured according to the present invention increase the proliferation and activity of T cells even without using CD3/CD28 antibody-bound magnetic beads and proliferate T cells by culturing a patient's own peripheral blood mononuclear cells and are not likely to cause side effects in the human body, and thus will be widely used as a novel T cell therapeutic agent. Furthermore, in the case of CD8+ T cells cultured as described above, the activity thereof increases, and thus, the CD8+ T cells can be used as a more effective therapeutic agent.